{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride+%28NaCl%29&page=57",
    "query": {
      "intervention": "0.9% Sodium Chloride (NaCl)",
      "page": 57
    },
    "page_size": 10
  },
  "pagination": {
    "page": 57,
    "page_size": 10,
    "total_count": 1987,
    "total_pages": 199,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride+%28NaCl%29&page=58&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride+%28NaCl%29&page=56&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T10:22:27.395Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06375512",
      "title": "A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Herpes Zoster"
      ],
      "interventions": [
        {
          "name": "HZ Vaccine (IN001)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Shingrix",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Shenzhen Shenxin Biotechnology Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "50 Years to 69 Years"
      },
      "enrollment_count": 150,
      "start_date": "2024-07-05",
      "completion_date": "2026-02-20",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-10-25T10:22:27.395Z",
      "location_count": 1,
      "location_summary": "Hollywood, Florida",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06375512"
    },
    {
      "nct_id": "NCT06317636",
      "title": "Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Pain",
        "Depression"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-01-28",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-10-25T10:22:27.395Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06317636"
    },
    {
      "nct_id": "NCT01790087",
      "title": "ANX-188 Thorough QT/QTc Study in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ANX-188 Therapeutic Dose",
          "type": "DRUG"
        },
        {
          "name": "ANX-188 Supratherapeutic dose",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mast Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 72,
      "start_date": "2013-02",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2015-05-20",
      "last_synced_at": "2026-10-25T10:22:27.395Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01790087"
    },
    {
      "nct_id": "NCT06079671",
      "title": "Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Volrustomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "15 Years and older · Female only"
      },
      "enrollment_count": 800,
      "start_date": "2023-09-22",
      "completion_date": "2030-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-25T10:22:27.395Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06079671"
    },
    {
      "nct_id": "NCT00890565",
      "title": "Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "granisetron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyowa Kirin Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 240,
      "start_date": "2009-05",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2024-06-17",
      "last_synced_at": "2026-10-25T10:22:27.395Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00890565"
    },
    {
      "nct_id": "NCT07453069",
      "title": "Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Vaginal Dysbiosis"
      ],
      "interventions": [
        {
          "name": "FB-301",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Chlorhexidine (0.5%) Vaginal Cleanse",
          "type": "OTHER"
        },
        {
          "name": "Sham vaginal cleanse (saline)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Freya Biosciences ApS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2026-07-22",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-25T10:22:27.395Z",
      "location_count": 4,
      "location_summary": "Wichita, Kansas • Waltham, Massachusetts • Charlotte, North Carolina + 1 more",
      "locations": [
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Waltham",
          "state": "Massachusetts"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07453069"
    },
    {
      "nct_id": "NCT05289037",
      "title": "COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "AS03",
          "type": "DRUG"
        },
        {
          "name": "BNT162b2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 (B.1.1.529)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 (B.1.351)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 bivalent (wildtype and Omicron BA.1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM [B.1.351]",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM/D614",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM/D614+B.1.351",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.351",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.529",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.617.2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium Chloride, 0.9%",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1270,
      "start_date": "2022-03-30",
      "completion_date": "2023-11-27",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-10-25T10:22:27.395Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05289037"
    },
    {
      "nct_id": "NCT02658877",
      "title": "Sputum-derived Cellular Targets After Xolair (Omalizumab)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 3,
      "start_date": "2016-01",
      "completion_date": "2018-07-19",
      "has_results": true,
      "last_update_posted_date": "2019-09-30",
      "last_synced_at": "2026-10-25T10:22:27.395Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02658877"
    },
    {
      "nct_id": "NCT04784767",
      "title": "PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium chloride, USP, for injection (0.9% NaCl)",
          "type": "DRUG"
        },
        {
          "name": "50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 29,
      "start_date": "2021-04-05",
      "completion_date": "2023-10-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-17",
      "last_synced_at": "2026-10-25T10:22:27.395Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04784767"
    },
    {
      "nct_id": "NCT00500565",
      "title": "Pain Management Following TRAM Flap for Breast Reconstruction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Saline",
          "type": "DRUG"
        },
        {
          "name": "Bupivicaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 61,
      "start_date": "2003-12",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2013-10-11",
      "last_synced_at": "2026-10-25T10:22:27.395Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00500565"
    }
  ]
}